Biosimilars are biologic medications that are slightly altered versions of already approved biologic disease modifying anti-rheumatic drugs (bDMARDs). They can be manufactured after the original product's patent protection expires. The advent of biosimilar use in pediatric rheumatology started with the biosimilar to infliximab in 2013. Since then, more biosimilars have been made available including etanercept, rituximab and adalimumab. This manuscript briefly reviews the history of biosimilar introduction to treatment and suggests strategies for the adoption of biosimilar drugs in services specialized in Pediatric Rheumatology, including potential barriers and solutions to their implementation into practice. The review covers general aspects relevant to all biosimilar drugs and specific examples covering individual drugs based on the experience of a large tertiary pediatric rheumatology service in the Northwest of England.

中文翻译：

---

小儿风湿病学中的生物仿制药及其在常规护理中的应用。

生物仿制药是生物药物，是已经批准的生物疾病修饰抗风湿药（bDMARD）的略有改动的版本。它们可以在原始产品的专利保护期满后制造。小儿风湿病中使用生物仿制药的问世始于2013年与英夫利昔单抗的生物仿制药。从那时起，出现了更多的生物仿制药，包括依那西普，利妥昔单抗和阿达木单抗。该手稿简要回顾了将生物仿制药引入治疗的历史，并提出了在小儿风湿病专科服务中采用生物仿制药的策略，包括其在实践中的潜在障碍和解决方案。